Germany Bladder Cancer Market to Reach $669.8 Million by 2035
Germany bladder cancer market is driven by the rising incidence of bladder cancer and increasing demand for advanced diagnostic and treatment solutions. Growing adoption of immunotherapy and precision-based oncology treatments, along with improving healthcare infrastructure, is further supporting market growth. Additionally, rising awareness regarding early cancer detection and expanding access to specialized oncology care are accelerating the use of advanced diagnostic and therapeutic procedures across Germany.
Browse the full report description of “Germany Bladder Cancer Market Size, Share & Trends Analysis Report, By Cancer Type (Transitional Cell Bladder Cancer/Urothelial Carcinoma, Squamous Cell Bladder Cancer, Adenocarcinoma, and Other Rare Types), By Diagnosis Method (Cystoscopy, Biopsy, Urinalysis, Urine Cytology, Intravenous Pyelogram (IVP), and Others), By Therapy (Chemotherapy, Immunotherapy, Radiation Therapy, Surgery, and Others), Forecast Period (2026–2035)” at https://www.omrglobal.com/industry-reports/germany-bladder-cancer-market
KEYTRUDA + PADCEV becomes new first-line standard (2024, EU-wide impact ? Germany adoption)
A major treatment shift occurred in 2024 when the European Commission approved the combination of Merck’s KEYTRUDA (pembrolizumab) and Padcev (enfortumab vedotin, ADC developed by Astellas/Seagen) for first-line treatment of advanced urothelial carcinoma. This approval is now influencing clinical practice across Europe, including gradual adoption in Germany’s hospital protocols. The combination has become the first regimen in decades to demonstrate superiority over platinum-based chemotherapy in the first-line setting, showing significant improvements in both overall survival and progression-free survival.
Germany Clinical Shift: Immunotherapy becomes backbone (2024–2025)
Germany witnessed a major clinical shift during 2024–2025, where PD-1 inhibitors such as Keytruda (pembrolizumab) and Opdivo (nivolumab) increasingly became the treatment backbone in urothelial carcinoma management. Combination therapies are progressively replacing traditional chemotherapy in advanced cases, particularly due to improved survival outcomes and better tolerability profiles. This trend is also expanding treatment access for metastatic urothelial carcinoma and cisplatin-ineligible patients across German oncology centers. A key example of this shift is the growing clinical use of nivolumab (Opdivo) in combination with chemotherapy for urothelial carcinoma, aligned with EU approvals and gradually expanding in Germany’s hospital treatment protocols.
About OMR Global
OMR Global is a market intelligence and strategic consulting firm specializing in growth advisory, competitive intelligence, and AI-enabled business research across global B2B industries.
The company supports enterprises, investors, and technology providers with actionable insights for market entry, investment analysis, procurement strategy, commercialization, and business expansion. OMR Global combines industry expertise, primary research, analytics, and digital intelligence tools to help organizations navigate evolving market landscapes and identify growth opportunities.
OMR Digital Offerings
- Pulse Intelligence Platform – AI-powered market intelligence suite designed to deliver analyst-grade insights faster and more efficiently. Built on 12+ years of research expertise and enhanced with AI-driven analytics, Pulse helps organizations transform large volumes of market and company data into actionable intelligence within hours instead of weeks. Trusted by Fortune 500 enterprises, global investment banks, strategy consultancies, and PE & VC firms, Pulse supports strategic decision-making across investment evaluation, competitive benchmarking, AI readiness, and market positioning.
Other Offerings
- Lead Generation – Verified B2B prospect data, ICP targeting, and intent-based sales intelligence
- RFx Support – End-to-end RFP, RFI, and RFQ support with vendor benchmarking and evaluation frameworks
OMR Global delivers data-driven intelligence solutions designed to support strategic decision-making, operational efficiency, and long-term business growth.
To find out more, visit www.omrglobal.com
Contact:
Mr. Anurag Tiwari
305-308, Commerce House, Janjeerwala Square,
Indore, Madhya Pradesh 452001
India
+91-780-304-0404